Ovarian Carcinosarcoma
Symptoms, Doctors, Treatments, Advances & More

Ovarian Carcinosarcoma Overview

Save information for later
Sign Up

Learn About Ovarian Carcinosarcoma

What is the definition of Ovarian Carcinosarcoma?
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.
What are the alternative names for Ovarian Carcinosarcoma?
  • Ovarian carcinosarcoma
  • MMMT of the ovary
  • Malignant mixed Müllerian tumor of the ovary
  • Malignant mixed mullerian tumor of the ovary
  • Ovarian malignant mixed Müllerian tumor
  • Ovarian malignant mixed epithelial mesenchymal tumor
Who are the top Ovarian Carcinosarcoma Local Doctors?
Elite in Ovarian Carcinosarcoma
Dr. Gary H. Altwerger
Obstetrics and Gynecology
Elite in Ovarian Carcinosarcoma
Dr. Gary H. Altwerger
Obstetrics and Gynecology
Referral may be required

UChicago Medicine Orland Park

14290 S. La Grange Rd., 
Orland Park, IL 
888-824-0200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Altwerger is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois. Dr. Altwerger is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hormone Replacement Therapy (HRT), and Hysterectomy.

Elite in Ovarian Carcinosarcoma
Elite in Ovarian Carcinosarcoma
Referral may be required

Northwell Health Physician Partners Surgical Specialties At Rego Park

95-25 Queens Boulevard, 5th Floor, 
Rego Park, NY 
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Joan Tymon-Rosario is an Oncologist practicing medicine in Rego Park, New York. Dr. Tymon-Rosario is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Malignant Mixed Mullerian Tumor, and Sertoli-Leydig Cell Tumor. Dr. Tymon-Rosario is board certified in American Board Of Obstetrics & Gynecology. Dr. Tymon-Rosario is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Ovarian Carcinosarcoma
Dr. Justin A. Harold
Obstetrics and Gynecology
Elite in Ovarian Carcinosarcoma
Dr. Justin A. Harold
Obstetrics and Gynecology
Referral may be required

MUSC Health Gynecology Oncology At Tidelands Health

4040 Hwy 17 Bypass, Suite 306, 
Murrells Inlet, SC 
843-792-9300
Experience:
10+ years
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Harold is an Obstetrics and Gynecologist practicing medicine in Murrells Inlet, South Carolina. He has been practicing medicine for over 10 years. Dr. Harold is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Hysterectomy, and Cystectomy. Dr. Harold is currently accepting new patients.

View All Doctors
What are the latest Ovarian Carcinosarcoma Clinical Trials?
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
Enrollment Status: Recruiting
Publish Date: August 07, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 3

Summary: This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Be...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Who is this study for: Patients with metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
Enrollment Status: Recruiting
Publish Date: June 01, 2026
Intervention Type: Drug, Combination product
Study Drug: Niraparib
Study Phase: Phase 2/Phase 3

Summary: Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of pati...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center